Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

被引：5
|
作者：
Weickhardt, A. J. [1 ]
Foroudi, F. [2 ]
Xie, J. [3 ]
Kanojia, K. [3 ]
Sidhom, M. [4 ]
Pal, A. [5 ]
Grimison, P. [6 ]
Zhang, A. [7 ]
Ng, S. [8 ]
Tang, C. [9 ]
Hovey, E. [10 ]
Chen, C. [11 ]
Hruby, G. [12 ]
Guminski, A. [12 ]
Mcjannett, M. [13 ]
Conduit, C. J. [14 ]
Lawrentschuk, N. [15 ]
Tran, B. [16 ]
Davis, I. D. [17 ]
Hayne, D. [18 ]
机构：
[1] Olivia Newton John Canc Wellness & Res Ctr, Med Oncol, Heidelberg, Vic, Australia
[2] Olivia Newton John Canc Wellness & Res Ctr, Radiat Oncol, Heidelberg, Vic, Australia
[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[4] Liverpool Hosp, Radiat Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[5] Liverpool Hosp, Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[6] Chris Obrien Lifehouse, Dept Med Oncol, Camperdown, NSW, Australia
[7] Chris Obrien Lifehouse, Med Oncol, Camperdown, NSW, Australia
[8] Sir Charles Gairdner Hosp, Med Oncol, Nedlands, WA, Australia
[9] Sir Charles Gairdner Hosp, Radiat Oncol, Nedlands, WA, Australia
[10] Prince Wales Hosp, Med Oncol, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia
[11] Prince Wales Hosp, Radiat Oncol, Nelune Comprehens Canc Ctr, Randwick, NSW, Australia
[12] Royal North Shore Hosp, Radiat Oncol, St Leonards, NSW, Australia
[13] ANZUP Canc Clin Trials, Clin Trials Res, Camperdown, NSW, Australia
[14] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[15] Peter MacCallum Canc Ctr, Urol, Melbourne, Vic, Australia
[16] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[17] Monash Univ, Med Oncol, Eastern Hlth Clin Sch, Box Hill, Vic, Australia
[18] Fiona Stanley Hosp, Urol, Murdoch, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1739P
引用
收藏
页码：S1332 / S1332
页数：1
相关论文
共 50 条
  • [21] A phase II clinical trial of toripalimab combined with cisplatin plus gemcitabine chemotherapy as neoadjuvant treatment for muscle-invasive bladder cancer
    Yang, Rong
    Li, Tianhang
    Zhang, Shun
    Zhang, Shiwei
    Guo, Hongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Preliminary results from a phase II clinical trial assessing the safety and efficacy of pembrolizumab in the treatment of highgrade cervical intraepithelial neoplasia
    Jimenez, Maria Garcia
    Lai, Tiffany
    Ferullo, Sylvia
    Walchonski, Jessica
    Chang, Yixuan
    Salani, Ritu
    Glaspy, John
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S289 - S290
  • [23] Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
    S A Hussain
    D D Stocken
    D R Peake
    J G Glaholm
    A Zarkar
    D M A Wallace
    N D James
    British Journal of Cancer, 2004, 90 : 2106 - 2111
  • [24] Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
    Hussain, SA
    Stocken, DD
    Peake, DR
    Glaholm, JG
    Zarkar, A
    Wallace, DMA
    James, ND
    BRITISH JOURNAL OF CANCER, 2004, 90 (11) : 2106 - 2111
  • [25] Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
    Gupta, Shilpa
    Fujii, Yasuhisa
    Van Der Heijden, Michiel Simon
    Weickhardt, Andrew James
    James, Nicholas D.
    Shariat, Shahrokh F.
    Michalski, Jeff M.
    Imai, Kentaro
    Fang, Xiao
    Kapadia, Ekta
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS720 - TPS720
  • [26] Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the atezobladderpreserve phase II trial (SOGUG-2017-A-IEC(VEJ)-4)
    Calvo, Ovidio Fernandez
    Bonfill, Teresa
    Madueno, Francisca Martinez
    Romero-Laorden, Nuria
    Sequero-Lopez, Silvia
    Domenech-Santasusana, Montserrat
    Sevillano, Elena
    Sanchez, Jose Garcia
    Roman, Pilar Canoa
    Alvarez-Fernandez, Carlos
    Vazquez-Estevez, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4).
    Vazquez-Estevez, Sergio
    Fernandez-Calvo, Ovidio
    Bonfill-Abella, Teresa
    Sequero, Silvia
    Martinez-Madueno, Francisca
    Romero-Laorden, Nuria
    Domenech-Santasusana, Montserrat
    Sevillano, Elena
    Sanchez, Jose Garcia
    Alvarez-Fernandez, Carlos
    Nunez-Gonzalez, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] The Efficacy and Safety of Hyperthermia Intravesical Chemotherapy in the Treatment of Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis
    Duan, Huanglin
    Deng, Zanxuan
    Zou, Junrong
    Zhang, Guoxi
    Zou, Xiaofeng
    Xie, Tianpeng
    UROLOGIA INTERNATIONALIS, 2024, 108 (04) : 322 - 333
  • [29] Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
    de Ruiter, Ben-Max
    van Hattum, Jons W.
    Lipman, Djoeri
    de Reijke, Theo M.
    van Moorselaar, R. Jeroen A.
    van Gennep, Erik J.
    Piet, A. H. Maartje
    Donker, Mila
    van der Hulle, Tom
    Voortman, Jens
    Oddens, Jorg R.
    Hulshof, Maarten C. C. M.
    Bins, Adriaan D.
    EUROPEAN UROLOGY, 2022, 82 (05) : 518 - 526
  • [30] Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meleis, Laura
    Moore, Russell
    Inman, Brant A.
    Harrison, Michael R.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (02) : 330 - 337
12345